We zijn nog hard aan het werk om een uitgebreide catalogus te maken met betere zoekfuncties en filters.
Tijdelijk kunt u gebruik maken van deze pagina om informatie te vinden van collecties die goedkeuring hebben gegeven om hun details te delen.
Gebruik de zoekfunctie hieronder om op deze pagina te zoeken.
Collectie details per study
Klik hieronder op een studie om de details te lezen.
Endoscope CRC Cohort (437)
Frailty in Uremia (459)
PRIMI (463)
EMPA-MVD (464)
FORCE-NEN (473)
BRIMM-HUM Study (474)
Archipelago (482)
STAR (486)
Biobank Huntington (495)
Cardiale Amyloidose (497)
AEO (504)
Prep4heat (505)
TUMAGNOSTIC (CP-506)
ProVag (509)
CVRM na PE (513)
STRONG II (515)
Youth-GEMs (519)
PRE DETECT-HF (526)
HealthySauna (532)
AtheroMaas (535)
OPTIMA (545)
Endoscope CRC Cohort (437)
| Name | Development and evaluation of diagnostic and prognostic biomarker profiles for ColoRectal Cancer and premalignant lesions |
| Acronym | Endoscope CRC cohort |
| Type | ☒ Cohort ☒ Cross-sectional ☒ Disease specific ☒ Hospital ☒ Population-based ☒ Other: cross-sectional with follow-up |
| Diseases studied | Malignant neoplasm of colon C18 Malignant neoplasm of rectosigmoid junction C19 Malignant neoplasm of rectum C20 Benign neoplasm of colon, rectum D12.0 – 12.8 |
| Description | The primary objectives of this study are: to identify and validate non-invasive biomarkers for pre-malignant and malignant colonic lesions, which can be used to aid CRC screening and improve polyp surveillance, with maximum true-negative rates, but low false-positive rates, with colonoscopy plus pathological evaluation as gold standard reference. Secondary, the obtained data will be the basis of the formation of a colorectal polyp and CRC-cohort and biobank (‘Endoscope-CRC biobank’). To set up a cohort and biobank of well-characterized patients for future translational studies on the pathophysiology and disease characteristics of premalignant and malignant colorectal lesions. The biobank includes blood plasma, DNA, faecal and breath samples, and permission will be asked to use histological material if obtained during endoscopy or surgery. |
| Material collected | ☒ Faeces ☒ Whole Blood |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 55 to 75 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 2000 |
Frailty in Uremia (459)
| Name | Frailty in Uremia: A survey on the effects of CKD 3-5 on physical functioning and – activity, quality of life and nutritional state. |
| Acronym | Frailty in Uremia |
| Type | ☒ Cohort ☒ Longitudinal |
| Diseases studied | Chronic kidney disease |
| Description | The number of patients with chronic kidney disease and end-stage renal disease is increasing rapidly. Chronic kidney disease has besides cardiovascular and metabolic complication also an effect on physical functioning, -activity and quality of life. Our primary objective is to assess the longitudinal effects of differences and changes in renal function at CKD stage 3-5 on physical functioning. The Secondary objectives is to look at the diffenrecens and changes at CKD stage 3-5 on physical activity, nutritional status, cardiovasculair function, quality of life, symptom burden, illness perception, anxiety and depression. The third objective is to assess the relation between different methods used to assess body composition with muscle strength hand physical activity. We will include 131 patients with CKD stage 3-5 and 65 healty controls where we will measure a selection of non-invasive techniques and laboratory parameters at inclusion and annually during follow up of four years. |
| Material collected | ☒ Plasma ☒ Serum ☒ Urine |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: >18 to … |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 196 |
PRIMI (463)
| Name | Preterm Immune system development and response to Immunization |
| Acronym | PRIMI study |
| Type | ☒ Cohort ☒ Longitudinal |
| Diseases studied | Immune system development of preterm born infants (born before 32 weeks GA) |
| Description | Primary objective is to study the antibody immune response to routine vaccinations in very preterm infants. (born before 32 weeks GA) Secondary aim is to study the immune system more extensively using flow cytometry, ELISA and single cell transcriptomics to measure development of antigen (Ag)-specific memory B cells raised in response to vaccination, and by using proteomics, epigenetics, and microbiome studies. |
| Material collected | ☒ Faeces ☒ Peripheral blood cells ☒ Plasma ☒ Serum |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 0 to 12 |
| Unit | ☐ Days ☐ Weeks ☒ Months ☐ Years |
| Number of donors | 120 preterm infants, 120 mothers of preterm infants, 25 controls (infants born > 37 weeks GA) |
EMPA-MVD (464)
| Name | SGLT2 inhibitors and microvascular dysfunction |
| Acronym | EMPA-MVD |
| Type | ☒ Cohort ☒ Longitudinal ☒ Other: RCT |
| Diseases studied | Heart failure with preserved ejection fraction |
| Description | A single centre prospective pre-post intervention study in patients with heart failure and preserved ejection fraction. Treatment with Empagliflozin will be initiated. Baseline and three months blood samples will be collected. |
| Material collected | ☒ Serum |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 50 to 85 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 50 |
FORCE-NEN (473)
| Name | InFrastructure fOr Rare Cancers in the nEtherlands – Neuroendocrine Neoplasms Multicenter Clinical Biobank |
| Acronym | FORCE-NEN |
| Type | ☒ Cohort ☒ Disease specific ☒ Longitudinal ☒ Rare Disease |
| Diseases studied | D3A/C7A – neuroendocrine neoplasms |
| Description | FORCE-NEN is a collaboration between the Dutch NEN expert centres in a multicenter clinical biobank aimed to create and maintain a comprehensive collection of clinicopathological data, imaging data and large-scale biobanking of donors with Neuroendocrine Neoplasms. Patients with a confirmed diagnosis of Neuroendocrine Neoplasm, ≥18 years or older and treated at one of the participating centres are eligible. From included patients clinical and imaging data will be collected for the biobank. For the majority of the donors blood (50ml) for the biobank will be collected at three timepoints: baseline, first evaluation and progression. For a subgroup (n=150) blood draws will be more frequent, at baseline, every evaluation after baseline with staging imaging and once between baseline and the first evaluation and once between first and second evaluation. |
| Material collected | ☒ Plasma ☒ Other: buffy coat |
| Sex | ☒ Female ☒ Male ☒ Not available |
| Age low – high | From: 18 to 99 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 45 |
BRIMM-HUM (474)
| Name | The effect of the indoor environmental quality on cognition and health |
| Acronym | HUM Study |
| Type | ☒ Other: Randomized |
| Diseases studied | Healthy |
| Description | To examine the effect of varying temperature and humidity combination on physiological parameters and cognition. The 4 conditions are 25C and 30% RH, 25C and 70% RH, 32C and 30% RH and lastly 32C and 70%RH. Participants are exposed for 8 hours in a day. Demographics taken include, age, weight, height, body fat %, VO2 submax, BMR, and estimated BSA. Primary measures are cognitive test scores, salivary cortisol level, metabolic rates, heart rate, skin temperature, core temperature, peripheral flows, sweat rate, and blood pressure. Salivary samples and blood pressure are every hour, metabolic rates and heart rates are continous. Cognitive tests are performed twice in a session once in the morning and once in the afternoon. |
| Material collected | ☒ Saliva |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 20 to 40 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 26 |
Archipelago (482)
| Name | Archipelago |
| Acronym | Ovarian tumor |
| Type | ☒ Disease specific ☒ Hospital ☒ Rare Disease |
| Diseases studied | 2C73 Malignant neoplasms of ovary 2C74 Malignant neoplasms of fallopian tube 2F76 Neoplasms of uncertain behaviour of female genital organs 2F32 Benign neoplasm of ovary |
| Description | https://www.aocr.nl/ Archipelago of Ovarian Cancer Research (AOCR) is a nationwide platform for scientific research on ovarian cancer. |
| Material collected | ☒ Plasma ☒ Tissue, cryo preserved ☒ Tissue, paraffin preserved |
| Sex | ☒ Female |
| Age low – high | From: 18 to 100 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | Nationwide 1000 patients |
STAR (486)
| Name | STudying Ageing in Rheumatoid arthritis (STAR) stored serum |
| Acronym | STAR stored serum |
| Type | ☒ Case-Control ☒ Cross-sectional |
| Diseases studied | ICD-10 M06.9 Rheumatoid arthritis |
| Description | The goal of the STudying Ageing in Rheumatoid arthritis (STAR) study is to gain insight into the effect of ageing on the result of disease activity measures, decline in cognition, physical activity and performance. In total, 420 patients with RA will be compared to 420 population controls between 55 and 85 years of age. In 180 participants (90 patients with RA and 90 population controls) one blood sample will be collected for the determination of CRP and ESR values, and serum will be stored for potential future analyses. |
| Material collected | ☒ Serum |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 55 to 85 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 180 |
BIOBANK HUNTINGTON (495)
| Name | Biobank Huntington MUMC+ |
| Acronym | BB-HD |
| Type | ☒ Case-Control ☒ Cohort ☒ Disease specific ☒ Longitudinal ☒ Rare Disease |
| Diseases studied | Huntington’s Disease, 8A01.10 |
| Description | The Huntington’s Disease (HD) Biobank enables future research into the early detection, progression, diagnosis, and treatment of Huntington’s disease, a severe neurodegenerative disorder caused by an expanded CAG repeat in the Huntingtin gene. HD is characterized by involuntary movements, cognitive decline, and neuropsychiatric symptoms. There is currently no cure, and treatments focus solely on symptom relief. By collecting biosamples and associated medical data, the biobank promotes future research towards a better understanding of the origin and progression of HD. Additionally, the biobank can be used to conduct research towards new treatments, aiding the development of potential disease-modifying interventions. This way, the biobank contributes to improving knowledge and care regarding HD. |
| Material collected | ☒ DNA ☒ Peripheral blood cells ☒ Plasma ☒ Saliva ☒ Serum ☒ Whole Blood ☒ Other: tearfluid and liquor |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 12 to … |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | Ongoing |
Cardiale Amyloidose (497)
| Name | Amyloid patients |
| Acronym | AMYLOID |
| Type | ☒ Cohort ☒ Longitudinal |
| Diseases studied | Cardiac amyloidosis |
| Description | A single center longitudinal cohort of patients with cardiac amyloidosis. Mostly transthyretin amyloidosis. |
| Material collected | ☒ Serum |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 50 to: 85 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 50 |
AEO (504)
| Name | Indoor air quality, temperature and cognitive performance study |
| Acronym | Aeolus |
| Type | ☒ Other: Intervention |
| Diseases studied | Healthy |
| Description | Participant are exposed to 4 conditions with a different temperature and ventilation combination. The 4 conditions are High Temp & High Vent (HTHV), High Temp & Low Vent (HTLV), Low Temp & High Vent (LTHV), and Low Temp & Low Vent (LTLV). The High Temp is 35C, the Low Temp is 23C both with 40% relative humidity. On each test day participants are exposed for 8 hours. Blood and saliva are taken 4 times a day. Also measured are skin temperature, core temperature, metabolic rates, breathing rates, heart rates, blood pressure and sweat weight. Moreover, participants will complete 2 cognitive tests and 2 stepping tasks once in the morning and once in the afternoon. |
| Material collected | ☒ Plasma ☒ Saliva ☒ Serum ☒ Whole Blood |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 18 to 40 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 22 |
Prep4Heat (505)
| Name | Preparing for heat waves |
| Acronym | Prep4heat |
| Type | ☒ Other: Non-randomized experimental trial |
| Diseases studied | Thermoregulation |
| Description | As the ongoing progression of global warming exposes individuals to extreme heat, there is increasing scientific interest to prevent medical emergencies caused during heat waves. Heat acclimation has been identified as a potential strategy to enhance thermoregulation and mitigate the adverse effects of heat stress. The study aims to assess the effect of passive heat acclimation, in combination with low-to-moderate intensity exercise, on cardiovascular, thermophysiological and metabolic responses in overweight, older individuals. |
| Material collected | ☒ Plasma ☒ Serum |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 60 to 80 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 12 |
TUMAGNOSTIC (CP-506)
| Name | TUMAGNOSTIC |
| Acronym | TUMAGNOSTIC |
| Type | ☒ Cohort ☒ Longitudinal |
| Diseases studied | C-00-C97 Malignant neoplasms |
| Description | A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumors or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumor and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial. We will evaluate blood-based hypoxia biomarkers at the same time points as imaging. We will investigate the potential of hypoxia-induced genes in blood liquid biopsies (cfDNA and circulating tumor cells) to predict the degree of tumor hyuposix a and its change during treatment. |
| Material collected | ☒ Peripheral blood cells ☒ Plasma |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 18 to … |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 126 |
ProVag (509)
| Name | ProVag – The effect of oral probiotics intake on the vaginal microbiota composition |
| Acronym | ProVag |
| Type | ☒ Other: Randomized controlled Trial |
| Diseases studied | Infertility |
| Description | Randomized, placebo-controlled double blind intervention that aims to elucidate whether oral probiotic treatment changes the vaginal microbiome profile of IVF patients from a low to a medium/high score (based on the receptIVFity test) compared to placebo treatment. Participants (n=110) with a low receptIVFity profile will receive probiotic or placebo treatment for 8 weeks. |
| Material collected | ☒ Other: Vaginal and rectal swabs |
| Sex | ☒ Female |
| Age low – high | From: 18 to 43 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 110 |
CVRM na PE (513)
| Name | Structured cardiovascular risk management in women with a history of preeclampsia |
| Acronym | CVRM after preeclampsia |
| Type | ☒ Cohort ☒ Longitudinal ☒ Other: Health care evaluation |
| Diseases studied | Preeclampsia; Hypertensive Disorders of Pregnancy |
| Description | As part of standard care, the Transmural Women’s Day Center offers repeated cardiovascular risk evaluations to women who have experienced preeclampsia, focusing on both somatic and cognitive/phsychological health sequalae. Former preeclamptic women are eligible for this health care program from as early as 6 months post-pregnancy up to decades thereafter. The offered risk evaluation includes laboratory analyses of venous blood and 24-hour urine, medical history taking, physical examination, 30-minutes blood pressure measurement, echocardiography, electrocardiogram, vascular function measurement, and questionnaires. Additional blood and urine samples are collected and stored at Biobank Maastricht from those who provide informed consent for this. |
| Material collected | ☒ DNA ☒ Plasma ☒ Serum ☒ Urine ☒ Whole Blood |
| Sex | ☒ Female |
| Age low – high | From: 25 to 65 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | Consecutive through health care. |
STRONG II (515)
| Name | Stereotactic body radiation therapy after chemotherapy for unresectable perihilar cholangiocarcinoma: a multicenter phase II trial |
| Acronym | STRONG II |
| Type | ☒ Cohort ☒ Disease specific ☒ Hospital |
| Diseases studied | Perihilar cholangiocarcinoma |
| Description | For patients with perihilar cholangiocarcinoma (pCCA), surgery is the only treatment modality that can result in cure. Unfortunately, most patients have unresectable tumors at presentation. The standard treatment for patients with unresectable pCCA is palliative chemotherapy (cisplatin and gemcitabine) which yields an estimated median overall survival (OS) of 12 months. In 2020 we completed a feasibility and phase I trial (STRONG 1) in six patients with stereotactic body radiation therapy (SBRT), delivered after chemotherapy to test its tolerability in patients with unresectable pCCA. We observed no dose-limiting toxicity (DLT), defined as grade ≥ 4 hepatobiliary or grade ≥ 3 gastrointestinal toxicity. The 12-month local tumor control rate was 80%, median survival was not reached, and there were no substantial changes in quality of life (QoL). The objective of the study is to confirm the efficacy of SBRT in a larger cohort of patients regarding local tumor control, toxicity, progression-free survival (PFS), OS, and QoL. Additionally, this study will include a translational part to explore the value of peripheral immunodynamics in predicting survival. |
| Material collected | ☒ Serum |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 18 to … |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 4 |
Youth GEMs (519)
| Name | Youth-GEMs |
| Acronym | Youth-GEMs |
| Type | ☒ Population-based |
| Diseases studied | (Risk of developing) Psychiatric Disorders |
| Description | These participants (age 12-24) are recruited after their first encounter with mental health services. They experience problems with mental health but are not necessarily diagnosed (yet). Data on demographics are available as well as clinical data and questionnaires. FU questionnaire data are possibly collected at 3, 6, 12, 18 and 24 months. Available biological samples include DNA and plasma. (Samples will be available in 2027.) To be able to work with the data, a publication proposal should be sent to the vice coordinator of Youth-GEMs: Sinan Gülöksüz |
| Material collected | ☒ DNA ☒ Plasma |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 12 to 24 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | Anticipated: ~800 – 1000 samples |
Pre-DETECT HF (526)
| Name | Pre-Symptomatic Detection of Impending Decompensation in Heart Failure through Voice Data (PRE-DETECT-HF) |
| Acronym | Pre-DETECT HF |
| Type | ☒ Cohort ☒ Longitudinal |
| Diseases studied | Heart failure |
| Description | I50 Heart failure |
| Material collected | ☒ Plasma |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: >18 to … |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 120 |
HealthySauna (532)
| Name | Healthy Sauna |
| Acronym | HealthySauna |
| Type | ☒ Longitudinal ☒ Population-based ☒ Other: Single arm experimental trial |
| Diseases studied | N/A |
| Description | The rising prevalence of overweight and obesity, along with its associated comorbidities represents a significant health concern that remains insufficiently addressed by current therapeutic options. An emerging alternative is the use of thermal interventions to enhance metabolic health. Sauna therapy present a generally well-tolerated and accessible treatment option combining both heat and cold, both of which have been shown to beneficially influence cardiometabolic health. This study will assess whether repeated exposure to infrared sauna followed by cold-water immersion improves glucose homeostasis in healthy overweight adults, a population at heightened risk for cardiovascular and metabolic disorders. Besides glucose homeostasis, thermophysiological, cardiovascular and metabolic measures, inflammatory markers, functional outcomes, muscle morphology, subjective perception and mental well-being will be assessed. |
| Material collected | ☒ Plasma ☒ Serum |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 40 to 75 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 16 |
ATHEROMAAS (535)
| Name | Carotid Atherosclerosis cohort Maastricht |
| Acronym | ATHEROMAAS |
| Type | ☒ Cohort ☒ Longitudinal ☒ Population-based |
| Diseases studied | Atherosclerosis |
| Co-morbidities, eg. Chronic kidney disease, diabetes | |
| Description | The AtheroMAAS study aims to investigate the underlying mechanisms of and risk factors for the development and progression of atherosclerosis, the main underlying cause of cardiovascular diseases. For this biobank, we collect not only atherosclerotic plaques from patients that undergo carotid endarterectomy, but also plasma and Peripheral Blood Mononuclear Cells (PBMCs) for analyses. From these patients, we also collect clinical information to study the impact of risk factors on disease progression, with a particular focus on patients with chronic kidney disease or diabetes. |
| Material collected | ☒ Peripheral blood cells ☒ Plasma ☒ Tissue, cryo preserved ☒ Tissue, paraffin preserved |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: >18 |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | Approximately 50/year |
OPTIMA (545)
| Name | Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer |
| Acronym | OPTIMA Study |
| Type | ☒ Cohort ☒ Disease specific ☒ Hospital ☒ Longitudinal |
| Diseases studied | Advanced Colorectal Cancer |
| Description | Background |
| Patients with advanced colorectal cancer (CRC) commonly receive irinotecan-based systemic treatment to alleviate symptoms, improve quality of life (QoL), and prolong overall survival (OS). However, predicting efficacy and toxicity of the treatment is challenging. Previous research indicated an association between the tumor molecular profile and response to irinotecan-based systemic treatment. Moreover, the UGT1A1 genotype of the patient, and the activity of the gut microbial enzyme β-glucuronidase (GUS) have been suggested as biomarkers for the development of systemic (e.g. neutropenia) and gastrointestinal toxicity (e.g. diarrhea) respectively. Therefore, the OPTIMA study will evaluate in patients with advanced CRC: 1. whether tumor molecular profiling can predict the efficacy of irinotecan-based systemic treatment; 2. whether high bacterial GUS enzyme activity is associated with increased gastrointestinal toxicity, decreased QoL and OS; as well as 3. the safety of a 70% irinotecan dose intensity in UGT1A1 poor metabolizers (PMs). |
|
| Methods | |
| This prospective, observational, multi-center cohort study will include patients with advanced CRC scheduled for irinotecan-based systemic treatment. Archived tumor tissue and routine CT/MRI scans at baseline and after four cycles will be used to investigate the association of tumor molecular profile and treatment response according to RECIST. Before treatment initiation, germline DNA obtained from whole blood will be genotyped using PCR to determine the UGT1A1*28 genotype, followed by 30% irinotecan dose reduction in UGT1A1 PMs. Bacterial GUS activity will be quantified in fecal samples collected before and during treatment by means of an enzyme activity assay and will be related to patient-reported gastrointestinal toxicity (mainly diarrhea). Additionally, patients will fill in questionnaires concerning QoL, medication use, medical history and comorbidities, dietary habits, as well as physical performance. OS will be documented, capturing the duration from the start of treatment until death from any cause. |
|
| Discussion | |
| Results obtained in the context of the OPTIMA study are expected to contribute to the optimization of efficacy and the reduction of toxicity of irinotecan-based systemic treatment, thereby potentially improving QoL of patients. Given that maintaining QoL is particularly critical in the palliative setting, the OPTIMA study has the potential to be of significant benefit for patients and their caregivers. |
|
| Material collected | ☒ Faeces ☒ Tissue, paraffin preserved ☒ Whole Blood |
| Sex | ☒ Female ☒ Male |
| Age low – high | From: 18 to … |
| Unit | ☐ Days ☐ Weeks ☐ Months ☒ Years |
| Number of donors | 104 |